8/14/2023 0 Comments Keynote 775 publicationMODULE 3: Diagnosis and Management of Adverse Events Associated with Immune Checkpoint Inhibitors Alone and in Combination for Endometrial Cancer - Dr Westin Potential ramifications of the emerging positive results from the RUBY and NRG-GY018 trials for the management of pMMR endometrial cancer.Response rates observed with single-agent dostarlimab among patients with recurrent and/or advanced pMMR disease in the GARNET trial.Design, eligibility criteria and key efficacy and safety endpoints for the Phase III LEAP-001 trial comparing pembrolizumab/lenvatinib to chemotherapy as first-line treatment for advanced or recurrent endometrial cancer estimated completion date.Antitumor efficacy observed with pembrolizumab/lenvatinib in patients with MSI-H/dMMR endometrial cancer in the KEYNOTE-775 trial current nonresearch role, if any.Key efficacy and safety data with pembrolizumab in combination with lenvatinib for patients with previously treated advanced pMMR tumors in the KEYNOTE-775 trial.Biologic rationale for combining immune checkpoint inhibitors with VEGF inhibitors for pMMR endometrial cancer.MODULE 2: Immunotherapy-Based Strategies for Patients with MMR-Proficient (pMMR) Endometrial Cancer - Dr Coleman Emerging positive results from the Phase III RUBY and NRG-GY018 studies evaluating dostarlimab and pembrolizumab, respectively, in combination with chemotherapy for advanced or recurrent endometrial cancer potential implications for the management of MSI-H/dMMR disease.Antitumor efficacy observed with pembrolizumab/lenvatinib among patients with MSI-H/dMMR endometrial cancer in the KEYNOTE-775 trial current nonresearch role, if any.Available clinical trial data with other anti-PD-1/PD-L1 antibodies (eg, durvalumab, atezolizumab) for patients with MSI-H/dMMR endometrial cancer.Current clinical roles for dostarlimab and pembrolizumab monotherapy in the treatment of MSI-H/dMMR advanced endometrial cancer optimal integration into practice.Efficacy and safety findings with pembrolizumab monotherapy for the cohort of patients with previously treated MSI-H/ dMMR advanced endometrial cancer in the KEYNOTE-158 study.Key efficacy and safety data with dostarlimab for patients with advanced or recurrent MSI-H/dMMR tumors in the.Current indications for MSI/MMR testing in patients with endometrial cancer available testing platforms.MODULE 1: Immune Checkpoint Inhibitors for Patients with Advanced Microsatellite Instability-High (MSI-H)/Mismatch Repair-Deficient (dMMR) Endometrial Cancer - Dr Powell 11:15 AM – 11:45 AM - Registration and Lunch Buffet
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |